Novo Nordisk tanks on financial guidance
Danish pharma major Novo Nordisk (NOV: N) has announced sales and operating profit growth at constant exchange rates (CER) for 2025 and released the 2026 full-year sales and operating profit outlook at CER, sending the firm’s shares down 16.2% to 307.85 kroner in early trading this morning.
The company also said the execution of Novo Nordisk’s overall share repurchase program for 2026 of up to 15 billion kroner will be initiated on February 4, 2026. g
In 2025, Novo Nordisk’s sales increased by 10% to 309.06 billion kroner ($49.16 billion) and operating profit increased by 6% to 127.66 billion kroner, compared to previously issued guidance of 8 to 11% sales growth and 4 to 7% operating profit growth. Sales in US Operations were positively impacted by gross-to-net sales adjustments. Diluted earnings per share were 23.03 kroner, up 2%.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Pharmaceutical
| Headless Content Management with Blaze